Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).

Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG.

Rheumatology (Oxford). 2005 Aug;44(8):1038-42. Epub 2005 May 3.

PMID:
15870145
2.

Gout medication treatment patterns and adherence to standards of care from a managed care perspective.

Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW.

Mayo Clin Proc. 2006 Jul;81(7):925-34.

PMID:
16835972
3.

Quality of care for gout in the US needs improvement.

Singh JA, Hodges JS, Toscano JP, Asch SM.

Arthritis Rheum. 2007 Jun 15;57(5):822-9.

4.

Allopurinol initiation and all-cause mortality in the general population.

Dubreuil M, Zhu Y, Zhang Y, Seeger JD, Lu N, Rho YH, Choi HK.

Ann Rheum Dis. 2015 Jul;74(7):1368-72. doi: 10.1136/annrheumdis-2014-205269. Epub 2014 Mar 24.

5.

Prevalence of treatment of hyperuricemic in patients admitted to the rheumatology ward and evaluation of compliance with the 2012 ACR Guidelines.

Banse C, Fardellone P, Paccou J.

Joint Bone Spine. 2014 Oct;81(5):461-2. doi: 10.1016/j.jbspin.2014.02.012. Epub 2014 Apr 2. No abstract available.

PMID:
24703403
6.

Opportunities for improving medication use and monitoring in gout.

Singh JA, Hodges JS, Asch SM.

Ann Rheum Dis. 2009 Aug;68(8):1265-70. doi: 10.1136/ard.2008.092619. Epub 2008 Aug 13.

PMID:
18701554
7.

Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.

Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA.

Rheumatology (Oxford). 2003 Feb;42(2):321-5.

PMID:
12595630
8.
9.

Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system.

Mikuls TR, Curtis JR, Allison JJ, Hicks RW, Saag KG.

J Rheumatol. 2006 Mar;33(3):562-6. Epub 2006 Feb 15.

PMID:
16482645
10.

Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.

Stevenson M, Pandor A.

Health Technol Assess. 2009 Oct;13 Suppl 3:37-42. doi: 10.3310/hta13suppl3/06. Review.

11.

Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.

Roddy E, Zhang W, Doherty M.

Ann Rheum Dis. 2007 Oct;66(10):1311-5. Epub 2007 May 15.

12.

Allopurinol adherence among patients with gout: an Italian general practice database study.

Mantarro S, Capogrosso-Sansone A, Tuccori M, Blandizzi C, Montagnani S, Convertino I, Antonioli L, Fornai M, Cricelli I, Pecchioli S, Cricelli C, Lapi F.

Int J Clin Pract. 2015 Jul;69(7):757-65. doi: 10.1111/ijcp.12604. Epub 2015 Feb 16.

PMID:
25683693
13.

Colchicine prescribing and safety monitoring in patients with gout.

Ly J, Gow P, Dalbeth N.

N Z Med J. 2007 Nov 9;120(1265):U2808.

PMID:
18264188
14.

Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.

[No authors listed]

Prescrire Int. 2009 Apr;18(100):63-5.

PMID:
19585722
15.

[Quality of treatment in gouty patients considering EULAR recommendations].

Radak-Perović M, Zlatković-Svenda M.

Srp Arh Celok Lek. 2012 Nov-Dec;140(11-12):717-21. Serbian.

16.

Utilization of allopurinol in the Australian community.

Chung Y, Lu CY, Graham GG, Mant A, Day RO.

Intern Med J. 2008 Jun;38(6):388-95. doi: 10.1111/j.1445-5994.2008.01641.x. Epub 2008 Apr 14.

PMID:
18422564
17.

Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.

Rashid N, Coburn BW, Wu YL, Cheetham TC, Curtis JR, Saag KG, Mikuls TR.

J Rheumatol. 2015 Mar;42(3):504-12. doi: 10.3899/jrheum.140588. Epub 2014 Dec 15.

18.

Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.

Zandman-Goddard G, Amital H, Shamrayevsky N, Raz R, Shalev V, Chodick G.

Rheumatology (Oxford). 2013 Jun;52(6):1126-31. doi: 10.1093/rheumatology/kes431. Epub 2013 Feb 7.

PMID:
23392592
19.

Febuxostat: a new treatment for hyperuricaemia in gout.

Edwards NL.

Rheumatology (Oxford). 2009 May;48 Suppl 2:ii15-ii19. doi: 10.1093/rheumatology/kep088. Review.

PMID:
19447778
20.

[Hyperuricemia, gout, pseudogout and concomitant diseases].

Schmidt BM, Wagner AD.

Dtsch Med Wochenschr. 2011 Dec;136(48):2489-91. doi: 10.1055/s-0031-1297274. Epub 2011 Nov 22. Review. German. No abstract available.

PMID:
22109583

Supplemental Content

Support Center